Publication | Open Access
The Immune Inhibitory Receptor LAIR-1 Is Highly Expressed by Plasmacytoid Dendritic Cells and Acts Complementary with NKp44 to Control IFNα Production
72
Citations
29
References
2010
Year
Adaptive Immune SystemInnate Immune SystemImmunologyImmune RegulationImmunologic MechanismCd4 T Cell ResponsesInnate ImmunityIfnα ProductionImmune SystemImmunotherapyImmune DysregulationPdc Inhibitory ReceptorInflammationTumor ImmunityActs ComplementaryCell SignalingAutoimmune DiseaseImmune SurveillanceAutoimmunityT Cell ImmunityImmune FunctionCell BiologyDendritic CellsPlasmacytoid Dendritic CellsImmune Cell DevelopmentDendritic Cell BiologyCellular Immune ResponseMedicine
Plasmacytoid dendritic cells (pDCs) are a subset of dendritic cells endowed with the capacity of producing large amounts of IFNα. Here we show that the Leukocyte-Associated Ig-like Receptor-1 (LAIR-1) is abundantly expressed on pDCs (the highest expression among all leukocytes) and its cross-linking inhibits IFNα production in response to Toll-like receptor ligands. Remarkably, LAIR-1 expression in pDCs is down-regulated in the presence of interleukin (IL)-3, thus indicating coordinated functions with NKp44, another pDC inhibitory receptor, which is conversely induced by IL-3. Nevertheless, the expression of NKp44 in pDCs isolated from secondary lymphoid organs, which is thought to be influenced by IL-3, is not coupled to a decreased expression of LAIR-1. Interestingly, pDCs isolated from peripheral blood of systemic lupus erithematosus (SLE) patients express lower levels of LAIR-1 while displaying slight but consistent expression of NKp44, usually undetectable on pDCs derived from healthy donors. Using sera derived from SLE patients, we show that LAIR-1 and NKp44 display synergistic inhibitory effects on IFNα production by interleukin IL-3 cultured pDCs stimulated with DNA immunocomplexes. In conclusion, our results indicate that the inhibitory function of LAIR-1 may play a relevant role in the mechanisms controlling IFNα production by pDCs both in normal and pathological innate immune responses.
| Year | Citations | |
|---|---|---|
Page 1
Page 1